Second Sight Medical Products Inc. (NASDAQ:EYES) previous close was $7.00 while the outstanding shares total 23.54M. The firm has a beta of 3.41. EYES’s shares traded lower over the last trading session, losing -7.14% on 06/18/21. The shares fell to a low of $6.42 before closing at $6.50. Intraday shares traded counted 3.25 million, which was 51.89% higher than its 30-day average trading volume of 6.75M. The stock’s Relative Strength Index (RSI) is 51.77, with weekly volatility at 12.80% and ATR at 0.78. The EYES stock’s 52-week price range has touched low of $0.69 and a $20.00 high.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Investors have identified the Medical Devices company Second Sight Medical Products Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $195.39 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Second Sight Medical Products Inc. (EYES) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For EYES, the company has in raw cash 26.86 million on their books with 2.2 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 27.62 million total, with 6.94 million as their total liabilities.
EYES were able to record -0.78 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by 23.68 million. In cash movements, the company had a total of -0.78 million as operating cash flow.
Is the stock of EYES attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 35.63%.
